Biotech Values

[DewDiligence]

Re: FoB programs

That MNTA will use some of the newly raised money to shore up the company's FoB programs isn’t merely a matter of opinion insofar as MNTA has told investors it is aggressively advancing these programs. Rick Shea emphasized the point in the BioWorld article posted today by jq1234 (#msg-57548823):

The company plans to use proceeds from the stock offering to fund the next programs within its pipeline, Richard Shea, the company’s senior vice president and chief financial officer, told BioWorld Today. “We’re making investments in follow-on biologics. We believe that will be a very important area for us over the next few years,” he said.